TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01688102

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral Vitamin D3
Description: 50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultraviolet Light
Description: 16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes
Study: NCT03116204

Intervention type: OTHER
Intervention: Assessment of score SAS
Description: Assessment of a score assessing physical and cognitive activities of patients in follow-up care and rehabilitation departments
Study: NCT02413788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined exercise
Description: aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: treadmill

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Study: NCT01037543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10460A or placebo or Neulasta
Description: Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10460A or placebo or Neulasta
Description: Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM10460A or placebo or Neulasta
Description: Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
Study: NCT03436654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended Pelvic lymphadenectomy
Description: To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended Pelvic lymphadenectomy
Description: To be performed concurrently with prostatectomy. Bilateral pelvic lymphadenectomy should include complete removal of all pelvic lymph nodes within the broad template described and includes the external iliac, hypogastric, obturator, and pre-sacral lymph nodes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist/antagonist
Description: Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist/antagonist
Description: Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Subjects undergo SBRT in cycle 4, then salvage radiation therapy in cycles 7-8. Treatment repeats every 28 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity
Study: NCT03623074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Use of lenses may reduce the rate of progression of juvenile myopia

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Use of lenses may reduce the rate of progression of juvenile myopia

Intervention type: DEVICE
Group type: OTHER
Intervention: Spectacle lenses
Description: Use of lenses may reduce the rate of progression of juvenile myopia
Study: NCT03599635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal bupivacaine
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Active Comparator
Study: NCT01100736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 125mg tablets, orally, twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan 100mg tablets, orally, once daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
Study: NCT03757520

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hand Grip Force
Description: For measuring the grip strength, the subjects will be asked to sit on a chair with their hip joint flexed at 90 degree, and shoulder joint in a neutral position.~The elbow is fixed at 90 degree flexion, forearm in a neutral position, and wrist at 0 to 15 degree radial deviation The test will be performed twice, and the higher value between the two measurements will be selected.
Study: NCT01100736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endothelin-3
Description: 5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endothelin-3
Description: 5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endothelin-3
Description: 5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
Study: NCT03703596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib (12mg QD PO d1-14, 21 days per cycle)
Study: NCT01929681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
Study: NCT01380613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workshop
Description: 10 session intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Workshop control
Description: 1 session intervention on standard HIV/STD information
Study: NCT00325780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Pitavastatin 4 mg once daily
Study: NCT03703596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (75mg/m2 IV d1, 21 days per cycle)
Study: NCT03660488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime 400 milligram Oral Capsule [Suprax]
Description: The intervention group will receive Cefixime 400mg, one tablet twice per day, for ten consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine Penicillin G
Description: The control group will receive Benzathine Penicillin G 2.4 Million Units intramuscularly for treatment of syphilis. Penicillin is the indicated treatment for syphilis infection
Study: NCT03415854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol (Zemplar)
Description: combination therapy
Study: NCT00679744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrimethamine
Description: Pyrimethamine will be given PO once daily for 8 consecutive weeks.
Study: NCT02399007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)
Description: SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)
Description: Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
Study: NCT00764504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Prosthesis
Description: For subjects with rotator cuff arthropathy and no previous shoulder device implanted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Prosthesis
Description: For subjects with rotator cuff arthropathy and no previous shoulder device implanted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Prosthesis
Description: For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
Study: NCT04592250

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT03295461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP+ 10% Emblica officinalis irrigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP + 0.2% Chlorhexidine irrigation)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP + 0.9% Saline irrigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRP +10% E. officinalis gel application.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: SRP+ placebo gel application.
Study: NCT03292211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: early standard intervention
Description: Conventional early in-bed activities within three days after stroke
Study: NCT03480867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Experimental: Registered one arm study Seven days of pre-operative Radiation+Temozolomide followed by surgery plus TMZ, as adjuvant component.for six cycles.
Study: NCT03480867

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pre-Operative Radiation
Description: Radiation is given with Temozolomide for 7 days before surgery
Study: NCT02724150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole High dose
Description: High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole Low dose
Description: low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
Study: NCT01851109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: genetic counseling
Description: The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:~1. A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;~2. Discuss how the results - positive or negative - affect cancer risk~3. Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);~4. Discuss how the test is conducted and what the results might be (positive, negative, uncertain);~5. Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc.
Study: NCT04872062

Intervention type: DEVICE
Intervention: NIV cards
Description: Reading the data available on the NIV cards

Intervention type: OTHER
Intervention: Medical file
Description: Using the data available in the medical file including clinical data, blood gas results, nocturnal oximetry results
Study: NCT02338609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: At the discretion of the investigator, pediatric patients could be treated with commercially available everolimus, as per local product information / standard of care. Treatment duration and dose modifications were at the investigator's discretion, as per the local product information.
Study: NCT04037397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti Arrhythmics
Description: Propafenone or Flecanide or Sotalol or Dofetilide or Dronedarone or Amiodarone. The subject must first fail a Class 1C or III drug prior to starting Amiodarone
Study: NCT00398333

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid enriched nutritional supplement
Description: Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
Study: NCT03711227

Intervention type: DIAGNOSTIC_TEST
Intervention: Procalcitonin lab test
Description: A procalcitonin order bundle will be created for admitted patients with pneumonia. This prepopulated bundle includes an initial and 24 hour procalcitonin level.
Study: NCT04285502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SURGICAL DRAIN
Description: A surgical drain is a tube used to remove blood, abscess and any type of fluid at the site of the place it is inserted
Study: NCT02635659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encapsulated nutrients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04037397

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation
Description: Approved Biosense Webster Inc. catheter devices should be used to perform RFCA. Ablation will be done to achieve entrance block into all pulmonary veins
Study: NCT01799954

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DNA-HIV-PT123
Description: 4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DNA-HIV-PT123
Description: 4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT1
Description: (along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT1
Description: (along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
Study: NCT06688357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedX 1116 Rehab Console
Description: This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MedX 1116 Rehab Console
Description: This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
Study: NCT01799954

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT1
Description: (along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT1
Description: (along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT4
Description: (along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
Study: NCT04351776

Intervention type: OTHER
Group type: OTHER
Intervention: VR-Biofeedback
Description: Participants will be instructed to use the Mindful Aurora application

Intervention type: OTHER
Group type: OTHER
Intervention: VR-Distraction
Description: Participants will be instructed to use one of three applications

Intervention type: OTHER
Group type: OTHER
Intervention: 360 Video
Description: Participants will be instructed which video to view
Study: NCT03799172

Intervention type: DRUG
Intervention: Echinocandin treatment
Description: Patients received echinocandins as a first-line therapy after candidemia diagnosis according to the standard of care

Intervention type: DRUG
Intervention: Triazole treatment
Description: Patients received triazoles as a first-line therapy after candidemia diagnosis according to the standard of care.~Candidemia was defined as at least one blood culture positive for Candida.
Study: NCT01863550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV
Study: NCT00736151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ralfinamide
Description: Oral tablets administered at rising doses of 80 - 320 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ralfinamide
Description: Oral tablets administered at rising doses of 80 - 320 mg/day
Study: NCT02292355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
Study: NCT02868879

Intervention type: OTHER
Intervention: Quantitative multiparametric and functional MRI
Description: Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2\*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks.

Intervention type: OTHER
Intervention: Quantitative multiparametric and functional MRI
Description: Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2\*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).~Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks.
Study: NCT01863550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT02776735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous
Study: NCT01863550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Optional correlative studies
Study: NCT01044433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study: NCT03396575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-DC vaccines with GM-CSF
Description: After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-DC vaccines with GM-CSF
Description: After chemoradiation subjects will receive the first cycle of dose-intensified TMZ followed by three biweekly TTRNA-DC vaccines with GM-CSF. Monthly DC vaccines will be given during TMZ Cycles 2-5 for Groups A and B and 48-96 hours after completion of TMZ Cycle 6 Day 21 for Group A and 12-36 hours after HSCs for Group B. All subjects will receive an additional two bi-weekly vaccines during Cycle 6 for a total of 10 DC vaccines. All DC vaccines will be embedded with GM-CSF (150 µg per injection) and given intradermal.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTRNA-xALT
Description: During TMZ Cycle 4 and with DC vaccine #6, an infusion of T-cells will be administered to all subjects.
Study: NCT01799954

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT4
Description: (along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT4
Description: (along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: NYVAC-HIV-PT4
Description: (along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AIDSVAX® B/E
Description: 300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
Study: NCT01468688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI571